The Cuprizone Mouse Model: A Comparative Study of Cuprizone Formulations from Different Manufacturers.
Cuprizone mouse model
astrogliosis
demyelination
microgliosis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Jun 2023
23 Jun 2023
Historique:
received:
30
05
2023
revised:
20
06
2023
accepted:
21
06
2023
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
The Cuprizone mouse model is widely used in studies on de- and remyelination. In the hands of different experimenters, the Cuprizone concentrations that lead to comparable levels of demyelination differ considerably. The reasons for this variability are unknown. In this study, we tested whether different Cuprizone formulations from different vendors and manufacturers influenced Cuprizone-induced histopathological hallmarks. We intoxicated male C57BL/6 mice with six Cuprizone powders that differed in their manufacturer, vendor, and purity. After five weeks, we analyzed the body weight changes over the course of the experiment, as well as the demyelination, astrogliosis, microgliosis and axonal damage by histological LFB-PAS staining and immunohistochemical labelling of PLP, IBA1, GFAP and APP. All Cuprizone formulations induced demyelination, astrogliosis, microgliosis, axonal damage and a moderate drop in body weight at the beginning of the intoxication period. In a cumulative evaluation of all analyses, two Cuprizone formulations performed weaker than the other formulations. In conclusion, all tested formulations did work, but the choice of Cuprizone formulation may have been responsible for the considerable variability in the experimental outcomes.
Identifiants
pubmed: 37445742
pii: ijms241310564
doi: 10.3390/ijms241310564
pmc: PMC10341492
pii:
doi:
Substances chimiques
Cuprizone
5N16U7E0AO
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
J Mol Neurosci. 2013 Jan;49(1):80-8
pubmed: 23054589
Beitr Pathol. 1975 Sep;156(1):56-64
pubmed: 1180820
Neurochem Int. 2009 Mar-Apr;54(3-4):192-8
pubmed: 19070638
Front Cell Neurosci. 2014 Mar 13;8:73
pubmed: 24659953
J Mol Neurosci. 2017 Apr;61(4):617-624
pubmed: 28238065
Brain. 2013 Jan;136(Pt 1):147-67
pubmed: 23266461
Glia. 2021 Apr;69(4):925-942
pubmed: 33245604
Cell Rep. 2015 Mar 24;10(11):1836-49
pubmed: 25801023
Neurosci Biobehav Rev. 2014 Nov;47:485-505
pubmed: 25445182
Neurosci Lett. 2009 Feb 13;451(1):83-8
pubmed: 19084049
J Neuroimmunol. 1998 Dec 1;92(1-2):38-49
pubmed: 9916878
Brain Pathol. 2009 Jul;19(3):467-79
pubmed: 19016742
Brain Res. 2016 Nov 1;1650:125-133
pubmed: 27592741
Nat Rev Dis Primers. 2018 Nov 8;4(1):43
pubmed: 30410033
J Neurosci. 2020 Nov 25;40(48):9327-9341
pubmed: 33106352
Brain Sci. 2022 Dec 08;12(12):
pubmed: 36552147
J Mol Neurosci. 2015 Oct;57(2):166-75
pubmed: 26067430
Cells. 2020 Mar 31;9(4):
pubmed: 32244377
Am J Pathol. 2008 Apr;172(4):1053-61
pubmed: 18349131
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Acta Neuropathol. 1981;53(2):93-8
pubmed: 7211208
J Neuroimmunol. 2013 Sep 15;262(1-2):128-31
pubmed: 23890807
Neurochem Res. 2007 Feb;32(2):279-92
pubmed: 17063394
Neuroimage. 2022 Apr 15;250:118935
pubmed: 35091079
Neurobiol Dis. 2010 Feb;37(2):362-9
pubmed: 19853662
Acta Neuropathol. 2009 Dec;118(6):723-36
pubmed: 19763593
Mol Neurodegener. 2022 May 7;17(1):34
pubmed: 35526004
Life Sci. 1967 Jan 1;6(1):11-9
pubmed: 6030552
Cells. 2020 Apr 11;9(4):
pubmed: 32290524
J Neuroimmunol. 2006 Jun;175(1-2):69-76
pubmed: 16626812
Sci Rep. 2021 Nov 19;11(1):22594
pubmed: 34799634
Glia. 2021 Jun;69(6):1583-1604
pubmed: 33620118